Molecular Partners AG Total Assets
Molecular Partners AG total assets. Based on the latest financial reports, Molecular Partners AG (MOLN) holds total assets worth CHF75.70 Million CHF (≈ $95.70 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Molecular Partners AG market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Molecular Partners AG (2013–2025)
Total assets of Molecular Partners AG from 2013 to 2025. This chart illustrates how Molecular Partners AG's total assets have evolved over time, based on quarterly financial data. See Molecular Partners AG share price for real-time trading data and today's change.
Molecular Partners AG - Asset Composition Analysis
Molecular Partners AG Total Assets Breakdown (December 2025)
Molecular Partners AG total assets breakdown as of December 2025. Molecular Partners AG's total assets of CHF75.70 Million consist of 94.9% current assets and 5.1% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 81.0% |
| Accounts Receivable | CHF1.30 Million | 1.3% |
| Inventory | CHF0.00 | 0.0% |
| Property, Plant & Equipment | CHF5.23 Million | 5.1% |
| Intangible Assets | CHF2.00K | 0.0% |
| Goodwill | CHF0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Molecular Partners AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Molecular Partners AG (MOLN) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Molecular Partners AG's current assets represent 94.9% of total assets in 2025, a decrease from 97.9% in 2013.
- Cash Position: Cash and equivalents constituted 81.0% of total assets in 2025, down from 87.3% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is property, plant & equipment at 5.1% of total assets.
Molecular Partners AG Competitors by Total Assets
Key competitors of Molecular Partners AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Molecular Partners AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.27 | 9.35 | 4.22 |
| Quick Ratio | 7.27 | 9.35 | 4.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CHF61.61 Million | CHF107.67 Million | CHF127.97 Million |
Molecular Partners AG - Advanced Valuation Insights
This section examines the relationship between Molecular Partners AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.22 |
| Latest Market Cap to Assets Ratio | 1.23 |
| Asset Growth Rate (YoY) | -35.6% |
| Total Assets | CHF102.11 Million |
| Market Capitalization | $125.91 Million USD |
Valuation Analysis
Above Book Valuation: The market values Molecular Partners AG's assets above their book value (1.23x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Molecular Partners AG's assets decreased by 35.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Molecular Partners AG (2013–2025)
The table below shows the annual total assets of Molecular Partners AG from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CHF102.11 Million ≈ $129.09 Million |
-35.59% |
| 2024-12-31 | CHF158.53 Million ≈ $200.42 Million |
-20.08% |
| 2023-12-31 | CHF198.35 Million ≈ $250.77 Million |
-24.37% |
| 2022-12-31 | CHF262.26 Million ≈ $331.56 Million |
+51.89% |
| 2021-12-31 | CHF172.67 Million ≈ $218.30 Million |
-7.93% |
| 2020-12-31 | CHF187.55 Million ≈ $237.11 Million |
+78.73% |
| 2019-12-31 | CHF104.94 Million ≈ $132.67 Million |
-32.37% |
| 2018-12-31 | CHF155.16 Million ≈ $196.16 Million |
+7.43% |
| 2017-12-31 | CHF144.42 Million ≈ $182.59 Million |
-21.55% |
| 2016-12-31 | CHF184.10 Million ≈ $232.75 Million |
-16.09% |
| 2015-12-31 | CHF219.40 Million ≈ $277.38 Million |
+13.08% |
| 2014-12-31 | CHF194.02 Million ≈ $245.29 Million |
+76.20% |
| 2013-12-31 | CHF110.11 Million ≈ $139.21 Million |
-- |
About Molecular Partners AG
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more